Abstract: Described herein are methods for quantitative target detection in a sample through use of microbeads and related devices and systems.

Abstract: Methods for identifying Quantifiable Internal Reference Standards (QIRS) for immunohistochemistry (IHC). Also disclosed are methods for using QIRS to quantify test antigens in IHC.

Abstract: Disclosed are compositions and methods for identifying and preferably quantifying single antigens/molecules in tissue sections and other cell preparations. The methods make use of specific antibodies or aptomers linked with beads or other micro-particles using bright field microscopy having the purpose to identify and quantify single antigens or other molecules.

Abstract: The present invention relates to methods for evaluating tissue pre-treatment such as ischemic time, fixation time and alcohol time in an immunohistochemical assay by using one or more internal controls. Said internal controls may be biomarker specific or tissue specific. Also included are uses and kits comprising said internal controls.

Abstract: Methods for identifying Quantifiable Internal Reference Standards (QIRS) for immunohistochemistry (IHC). Also disclosed are methods for using QIRS to quantify test antigens in IHC.

Abstract: Described herein are methods for quantitative target detection in a sample through use of microbeads and related devices and systems.

Abstract: Multi-valve autoregulatory microfluidic devices and methods are described. The described devices and methods offer improved performance and new means of tuning autoregulatory effects in microfluidic devices.

Abstract: An immunochemical and molecular biologic endpoint reporter system in which reaction products, coupled to electrochemically active molecules susceptible to redox recycling or coupled to enzymes capable of proportional generation of said electrochemically active molecules, are detected and/or quantitated using amperiometry in conjunction with a silicon microchip possessing a closely spaced interdigitated array of nobel metal electrodes.

Abstract: Disclosed are methods for identifying the presence of a tumor in a mammal, comprising the steps of obtaining an antibody against cell ghosts, wherein the antibody is specific to an intracellular antigen not present on the cell surface of normal or neoplastic cells, and wherein the antibody is labeled with a label capable of being imaged; administering the antibody to the mammal, thereby permitting the antibody to bind preferentially to necrotic tissue; and imaging the binding of the antibody to the necrotic tissue, wherein a localized concentration of said antibody is indicative of the presence of a tumor. The antibodies used in these methods are preferably monoclonal antibodies, are also preferably specific for one or more nuclear proteins, and are also preferably labeled with one or more radionuclides. Also disclosed are antibodies for use with the foregoing methods.

Abstract: Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor.

Abstract: Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor.

Abstract: A cell-surface glycoprotein, termed luminal epithelial antigen, having a molecular weight of 135 Kd and which is present in normal mammary epithelial cell lines but not in malignant epithelial cell lines. A monoclonal antibody directed against said luminal epithelial antigen. Use of the monoclonal antibody in a diagnostic assay for the early identification of patients with high risk of developing breast cancer and in a prognostic assay for the prediction of recurrence of breast cancer in patients.

Abstract: The invention relates to a new antigen termed BLA-36 specifically expressed on the surface of Hodgkin's cells, Reed-Sternberg cells and B lymphocytes, and to a new monoclonal antibody (anti-BLA-36) specific thereto. The antigen is characterized by the following properties:a molecular weight of about 36,000 D;the presence of an epitope recognized by antibody to said protein;specific expression by Hodgkin's cells and Reed-Sternberg cells in all subsets of Hodgkin's disease, and by activated and early proliferating B cells;no expression by T cells;capability of reacting with its antibody in both frozen and fixed/paraffin embedded tissues;a function associated with the growth of cells capable to express said antigen protein.

Abstract: An inverter is connected between the control nodes of two transistors in a current mirror system which forms a closed current feedback loop. Any difference between the bias voltages at the input and output of the inverter is reduced to zero. The self-biasing inverter amplifier may comprise the active part of an oscillator but may also be used as a level shifter or a reference circuit.

Abstract: The invention relates to a new antigen termed BLA-35 specifically expressed on the surface of Hodgkin's cells, Reed-Sternberg cells and B lymphocytes, and to a new monoclonal antibody (anti-BLA-36) specific thereto. The antigen is characterized by the following properties:a molecular weight of about 36,000 D;the presence of an epitope recognized by antibody to said protein;specific expression by Hodgkin's cells and Reed-Sternberg cells in all subsets of Hodgkin's disease, and by activated and early proliferating B cells;no expression by T cells;capability of reacting with its antibody in both frozen and fixed/paraffin embedded tissues;a function associated with the growth of cells capable to express said antigen protein.

Abstract: Disclosed is a method for enhancing the effects of therapy that kills malignant cells in vivo comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of a mammal but not to external cellular components, wherein the monoclonal antibody is attached to an antineoplastic agent; initiating therapy in a mammal to kill malignant cells in vivo, thereby causing some of the malignant cells to become necrotic; and administering the antibodies to the mammal. The antibodies bind to the necrotic malignant cells thereby delivering antineoplastic agent to surrounding cells. Also disclosed is a method of de novo therapy comprising administration of antibody-antineoplastic agent conjugate such that antineoplastic agent is delivered to the tumor. Also disclosed are antibodies for use with the foregoing methods and for use with diagnositc methods.

Abstract: An integrated circuit device including a substrate (2), power supply buses (V.sub.DD, V.sub.SS), and a number of terminal pads (1) has an electrostatic discharge protection circuit associated with one of its terminal pads (1). The protection circuit comprises a diode (D1) directly connected between the pad (1) and one of the power supply buses (V.sub.DD, V.sub.SS), a punchthrough transistor (TR1) directly connected to the other one of the power supply buses (V.sub.DD, V.sub.SS) and a resistive path (R1) connecting the pad (1) to the remainder of the integrated circuit. Static charges applied to the pad (1) are transmitted to the one or the other power supply bus (V.sub.DD, V.sub.SS) via the diode (D1) or the punchthrough transistor (TR1) rather than being transmitted to the remainder of the integrated circuit.

Abstract: Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor.

Abstract: A variable motor speed control arrangement of the tachogenerator feedback loop type comprises a triac (5) connected in series with the motor (M). The triac is fired in each half cycle of the AC mains supply. The firing angle of the triac is varied to provide the required control. The arrangement employs a single cycling counter (CT) to time the interval between two output pulses of the tachogenerator (T) in order to determine the current motor speed and also to provide a count-down from the beginning of each half cycle to the required firing instant. The control processes are carried out in periods beginning at each counter overflow instant. This breaking up of the processing, together with the use of the single counter allows a microcomputer (1), which is running other programs to provide the speed control in addition.